As for CD8 positive T cells, a study involving 24 ES-SCLC patients receiving first-line chemo-immunotherapy showed that the density of CD8 positive cells in the tumor stroma was significantly decreased in long-term survivors[55]. This evidence concerns the gene CD8A and neoplasm.